UK pilot of DoH-ABPI "toolkit"

10 March 2008

A new joint working scheme in the UK between the Association of the British Pharmaceutical Industry and Ashton, Leigh and Wigan Primary Care Trust has been announced, the day after the launch of a government-industry "toolkit" designed to encourage such cooperation. The pilot venture involves bringing additional resources to the PCT as it commissions programs to evaluate patients' conditions against the treatment they are receiving and to find better ways of providing care.

For drugmakers, there is the opportunity to deepen their knowledge and understanding of how they can help other National Health Service organizations to implement this new agenda.

Martin Anderson, the ABPI's director of NHS policy and partnerships, said: "targeted and ethical joint working between the industry and the NHS can bring great benefits to patients and the NHS, and this latest cooperative venture is a prime example of the sort of endeavor that we and the government are seeking to encourage." He added that "the new guidance and its associated toolkit, issued jointly by the Department of Health and the ABPI, encourage PCTs to work with the industry in appropriate areas. It is in everyone's interest to do so - as this latest agreement with Ashton, Leigh and Wigan PCT demonstrates."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight